Gregory Lucier joins Avantor (NYSE: AVTR) Board as new director

Rhea-AI Filing Summary

Avantor, Inc. reported that its Board of Directors elected Gregory Lucier as a director, effective October 3, 2025, with an initial term running until the 2026 Annual Meeting of Stockholders. The Board determined he meets New York Stock Exchange and Exchange Act independence standards.

Lucier is Executive Chairman and CEO of Corza Medical and previously led NuVasive and Life Technologies, with earlier leadership roles at General Electric. He will receive Avantor’s standard non-employee director compensation, including a prorated $95,000 annual cash retainer and restricted stock units with a grant date fair value of $210,000, vesting in full one year after grant. Avantor also issued a press release announcing his election, furnished as Exhibit 99.

false000172248200017224822025-10-012025-10-010001722482us-gaap:CommonStockMember2025-10-012025-10-01

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2025

Avantor, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-38912			82-2758923
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

Radnor Corporate Center, Building One, Suite 200

100 Matsonford Road

Radnor, Pennsylvania 19087

(Address of principal executive offices, including zip code)

(610) 386-1700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Exchange on which registered

Common Stock, $0.01 par value

AVTR

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 1, 2025, the Board of Directors (the “Board”) of Avantor, Inc. (the “Company”), upon the recommendation of its Nominating and Governance Committee, elected Gregory Lucier as a director, effective as of October 3, 2025, with an initial term expiring on the date of the Company’s 2026 Annual Meeting of Stockholders.

Mr. Lucier, age 61, currently serves as the Executive Chairman and Chief Executive Officer of Corza Medical, a surgical technologies company, since 2021. Prior to Corza Medical, Mr. Lucier served as the Chairman and Chief Executive Officer of NuVasive, Inc., a global technology leader in minimally invasive spine and orthopedic surgery, from 2015 to 2021. Prior to NuVasive, Mr. Lucier served as Chairman and CEO of Life Technologies, a global life sciences company, from 2003 to 2014. Mr. Lucier’s early career included roles as a corporate officer of General Electric Company and as an executive at GE Medical Systems Information Technologies. He currently serves on the board of directors of Maravai Lifesciences Holdings, Inc. and as non-executive chairman of the board of Dentsply Sirona, Inc. In the past five years, he has served as a director on the boards of each of Catalent Inc. and PhenomeX Inc. Mr. Lucier holds an MBA from Harvard Business School and a bachelor’s degree in industrial engineering from Pennsylvania State University.

The Board has determined that Mr. Lucier meets all applicable requirements to serve on the Board, including without limitation, the applicable independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

There are no arrangements or understandings with any other persons pursuant to which Mr. Lucier was selected as a director of the Company and he does not have a direct or indirect material interest in any, or any currently proposed, transaction in which the Company was or is a participant that requires disclosure under Item 404(a) of Regulation S-K.

Mr. Lucier is eligible to receive the standard compensation applicable to all non-employee directors of the Company: (1) an annual cash retainer of $95,000 (prorated based on his service during 2025), paid quarterly in arrears and (2) a grant of a number of restricted stock units with a grant date fair value equal to $210,000, divided by the closing price per share of the Company’s common stock on the date of his election (prorated based on his service prior to the 2026 Annual Meeting). The restricted stock units are scheduled to vest in full one year from the grant date, subject to his continued service as a director through that date.

Item 7.01.    Regulation FD Disclosure.

On October 3, 2025, the Company issued a press release announcing Mr. Lucier’s election to the Board. A copy of the press release is furnished herewith as Exhibit No. 99 to this Current Report on Form 8-K, and shall not be deemed filed for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99						Press Release, dated October 3, 2025
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Avantor, Inc.
Date: October 3, 2025			By:			/s/ Claudius Sokenu
						Name:			Claudius Sokenu
						Title:			Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary (Duly Authorized Officer)

FAQ

What did Avantor (AVTR) announce about its Board of Directors?

Avantor announced that its Board of Directors elected Gregory Lucier as a director, effective October 3, 2025. His initial term will expire at the company’s 2026 Annual Meeting of Stockholders, and he will receive the standard compensation package for Avantor’s non-employee directors.

Who is Gregory Lucier, the new Avantor (AVTR) director?

Gregory Lucier is Executive Chairman and Chief Executive Officer of Corza Medical, serving in that role since 2021. He previously served as Chairman and CEO of NuVasive and Life Technologies, and earlier held corporate officer and executive positions at General Electric and GE Medical Systems Information Technologies.

How will Gregory Lucier be compensated as an Avantor (AVTR) director?

Gregory Lucier will receive Avantor’s standard non-employee director compensation, including a $95,000 annual cash retainer, prorated for 2025 and paid quarterly. He will also receive restricted stock units with a grant date fair value of $210,000, prorated and scheduled to vest in full one year from grant.

Is Gregory Lucier considered an independent director at Avantor (AVTR)?

Avantor’s Board determined that Gregory Lucier meets all applicable requirements to serve on the Board, including independence standards. These standards are those of the New York Stock Exchange and the Securities Exchange Act of 1934, as amended, according to the company’s disclosure in this report.

Does Gregory Lucier have related-party transactions with Avantor (AVTR)?

Avantor states that Gregory Lucier has no arrangements or understandings with other persons regarding his selection as director. The company also notes he has no direct or indirect material interest in any current or proposed transaction requiring disclosure under Item 404(a) of Regulation S-K.

What disclosure did Avantor (AVTR) provide under Regulation FD regarding Gregory Lucier?

Avantor disclosed that it issued a press release on October 3, 2025, announcing Gregory Lucier’s election to the Board. The press release is furnished as Exhibit 99 and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.